ARS Pharmaceuticals, Inc. (SPRY) P/S ratio

P/S ratio today
4.3×

ARS Pharmaceuticals, Inc. (SPRY) trades at 4.3× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 13.6×. That is 12.4% higher than the 12.1× of fiscal 2024. Figures as of 18 Nov 2026, 03:16 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio today
4.3×
P/S ratio, fiscal 2025
13.6×
Change on fiscal 2024
+12.4%
Highest on record
259.0×fiscal 2022
Lowest on record
12.1×fiscal 2024
Fiscal years on record
42021–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

ARS Pharmaceuticals, Inc. P/S ratio, in more detail

Today's figure is 68.7% below the fiscal 2025 year-end.

Across the 4 fiscal year-ends on record (2021–2025), the highest was 259.0× in fiscal 2022 and the lowest 12.1× in fiscal 2024. Today's P/S ratio is at or below every one of the 4 fiscal year-ends on record; their median is 24.3×.

History · 4 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

ARS Pharmaceuticals, Inc. P/S ratio, year by year

ARS Pharmaceuticals, Inc. (SPRY) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today4.3×—$3.65—
202513.6× 12.4% up$11.65$0.86
202412.1×—$10.55$0.87
2023——$5.48$0.00
2022259.0× 641.6% up$8.53$0.03
202134.9×—$6.66$0.19
2020——$46.34—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

More on SPRY

ARS Pharmaceuticals, Inc., figure by figure

ARS Pharmaceuticals, Inc. (SPRY) overview: price, valuation and scorecard

ARS Pharmaceuticals, Inc. P/S ratio: questions and answers

What is ARS Pharmaceuticals, Inc.'s P/S ratio?

ARS Pharmaceuticals, Inc. (SPRY) trades at 4.3× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 13.6×. That is 12.4% higher than the 12.1× of fiscal 2024.

Is ARS Pharmaceuticals, Inc.'s P/S ratio high or low compared with its own history?

Today's P/S ratio is at or below every one of the 4 fiscal year-ends on record; their median is 24.3×.

What are the highest and lowest P/S ratio figures on record for ARS Pharmaceuticals, Inc.?

Across the 4 fiscal year-ends on record (2021–2025), the highest was 259.0× in fiscal 2022 and the lowest 12.1× in fiscal 2024.

How is ARS Pharmaceuticals, Inc.'s P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “ARS Pharmaceuticals, Inc. (SPRY) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/SPRY/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.